Literature DB >> 9494159

[Treatment of stage I nonseminomatous testicular cancer with one cycle of adjuvant chemotherapy].

D Corti Ortíz1, A Fonerón Burgos, L Troncoso Schifferli.   

Abstract

On May 1990, we began a treatment protocol for testicular stage I nonseminomatous cancer, with one chemotherapy cycle consisting of a cisplatin based combination of drugs. Until July 1996 we had admitted 18 patients, presenting five of them embryonal carcinoma and three yolk sac tumors. So far, with a median follow-up of 46.9 months, we had not relapses. 11 patients have normal long term semen analysis, with two achieving pregnancy. We believe this is acceptable alternative for treating stage I nonseminomatous cancer with scarce drugs adverse reactions. The convenience of selecting patients previous admittance, is discussed.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9494159

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN： 0210-4806            Impact factor:   0.994


  3 in total

1.  [Testicular cancer--is there an indication for adjuvant or neoadjuvant systemic therapy?].

Authors:  S Langenkamp; P Albers
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

2.  [Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I].

Authors:  M Hartmann; R Siener; S Krege; H Schmelz; K-P Dieckmann; A Heidenreich; P Kwasny; M Pechoel; J Lehmann; S Kliesch; K-U Köhrmann; R Fimmers; L Weissbach; V Loy; C Wittekind; P Albers
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

3.  Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study.

Authors:  Klaus-Peter Dieckmann; Tomas Pokrivcak; Lajos Geczi; David Niehaus; Inken Dralle-Filiz; Cord Matthies; Tamas Dienes; Stefanie Zschäbitz; Pia Paffenholz; Tanja Gschliesser; Renate Pichler; Michal Mego; Pia Bader; Friedemann Zengerling; Julia Heinzelbecker; Philipp Krausewitz; Susanne Krege; Gaetano Aurilio; Cem Aksoy; Marcus Hentrich; Christoph Seidel; Péter Törzsök; Tim Nestler; Matthaeus Majewski; Andreas Hiester; Tomas Buchler; Sonia Vallet; Hana Studentova; Sandra Schönburg; Dora Niedersüß-Beke; Julia Ring; Emanuela Trenti; Axel Heidenreich; Christian Wülfing; Hendrik Isbarn; Uwe Pichlmeier; Martin Pichler
Journal:  Ther Adv Med Oncol       Date:  2022-03-31       Impact factor: 8.168
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.